VRPX Key Statistics, Chart & Performance
The current stock price of VRPX is 0.6695 USD. In the past month the price decreased by -85.68%. In the past year, price decreased by -99.31%.
VRPX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.35 | 1.03T | ||
| JNJ | JOHNSON & JOHNSON | 19.82 | 495.71B | ||
| MRK | MERCK & CO. INC. | 12.6 | 275.48B | ||
| PFE | PFIZER INC | 7.9 | 143.79B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.80B | ||
| ZTS | ZOETIS INC | 20.01 | 55.90B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.8 | 23.24B | ||
| VTRS | VIATRIS INC | 5.41 | 14.51B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.21 | 11.55B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.45B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.72B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About VRPX
Company Profile
Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. The company is headquartered in Berwyn, Pennsylvania and currently employs 2 full-time employees. The company went IPO on 2021-02-17. The firm is focused on developing novel and proprietary drug delivery systems across various pain indication. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.
Company Info
VIRPAX PHARMACEUTICALS INC
1055 Westlakes Drive, Suite 300
Berwyn PENNSYLVANIA 19380 US
CEO: Anthony Mack
Employees: 7
Phone: 16107274597
VIRPAX PHARMACEUTICALS INC / VRPX FAQ
What does VIRPAX PHARMACEUTICALS INC do?
Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. The company is headquartered in Berwyn, Pennsylvania and currently employs 2 full-time employees. The company went IPO on 2021-02-17. The firm is focused on developing novel and proprietary drug delivery systems across various pain indication. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.
What is the current price of VRPX stock?
The current stock price of VRPX is 0.6695 USD. The price decreased by -45.12% in the last trading session.
What is the dividend status of VIRPAX PHARMACEUTICALS INC?
VRPX does not pay a dividend.
What is the ChartMill technical and fundamental rating of VRPX stock?
VRPX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
How is the valuation of VIRPAX PHARMACEUTICALS INC (VRPX) based on its PE ratio?
VIRPAX PHARMACEUTICALS INC (VRPX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.29).
VRPX Technical Analysis
VRPX Financial Highlights
Over the last trailing twelve months VRPX reported a non-GAAP Earnings per Share(EPS) of -5.29. The EPS increased by 59.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -775.73% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |